Ruixin Medical Showcases AI-Powered Surgical Robotics Platform at 2025 China Medical Equipment Conference, Leading a New Era of Precision Cardiovascular Care
RaysightMed
Medical Imaging Product Developer
From March 13 to 16, 2025, the China Medical Equipment Conference and Medical Equipment Exhibition will be held in Chongqing. RaysightMed, as the pioneer and leader in AI large models + surgical robotics for precision cardiovascular diagnosis and treatment, will showcase its integrated hardware and software intelligent diagnosis and treatment product portfolio at the exhibition. This participation not only demonstrates its technological leadership but also, in collaboration with industry partners, launches the "Chinese brand heart...""Catheterization Lab Comprehensive Solutions" to Drive Ecosystem Innovation for High-End Medical Equipment Made in China.
AI + Surgical Robot Closed-loop Ecosystem Draws High Attention at the Scene
RaysightMed showcased the world's first AI large model + surgical robot cardiovascular precision diagnosis and treatment platform on site, attracting many hospital administrators, clinical experts, and investment institutions to stop by for consultation.
Participate in ExhibitionsHospital Administrators Consult RaysightMed Solutions
In the preoperative evaluation area, Ruixin-FFR, developed by RaysightMed, is the world's first non-invasive coronary blood supply function assessment CT-FFR product based on AI and three-dimensional computational fluid dynamics (3D-CFD). By combining the advantages of non-invasive coronary CT angiography (CCTA) and fractional flow reserve (FFR) technology, it can accurately evaluate coronary stenosis from both morphological and functional perspectives. Integrated with the coronary CT angiography intelligent processing software — RuiXin-CoronaryAI, it precisely identifies and locates plaque types. The intelligent calcium scoring system, RuiXin-CaScore, accurately measures the degree of coronary atherosclerosis, while the surgical planning decision-support platform, RuiXin-Planner, provides preoperative planning design to reduce surgical risks, significantly decrease misdiagnosis and missed diagnosis rates, and enhance diagnostic accuracy.
In the intraoperative diagnosis and intelligent treatment area, Angio QFA 100 with contrast FFR achieves a breakthrough by providing a one-stop macro and micro assessment of coronary function. Combined with the cardiovascular interventional surgical robot, it enables personalized surgical planning and computer-assisted precision in operation execution. In the postoperative intelligent management area, Ruixin-FFR (RaysightMed FFR) can evaluate the patient's postoperative coronary prognosis and offer personalized rehabilitation plans.
This shows that the RaysightMed AI large model + surgical robot cardiovascular precision diagnosis and treatment platform has truly achievedA full-course diagnosis and treatment solution covering "preoperative assessment - intraoperative diagnosis and intelligent treatment - postoperative intelligent management"。
Leading with a Class III Product Matrix, Co-building "Autonomous Brand Cardiac Catheterization Lab"
Particularly noteworthy is that at this exhibition, the product of RaysightMed, which has been approved by the National Medical Products Administration (NMPA) for a Class III medical device registration certificate, achieved deep integration with other well-known brands' cardiac catheterization lab products, jointly forming the "Comprehensive Solution for Domestic Brand Cardiac Catheterization Labs." The launch of this solution not only highlights RaysightMed's pioneering role and technological leadership in the field of cardiovascular interventional diagnosis and treatment but also reflects its sense of social responsibility in promoting industry self-control and advancing the upgrading of domestically produced medical equipment in China.
RaysightMed's Class III certified products include Ruixin-FFR, Raysight Angio QFA 100, RuiXin-Coronary AI, and disposable invasive blood pressure sensors. Among them, the Raysight Angio QFA 100 is equipped with RaysightMed's uniqueComputational Fluid Dynamics + AI Fusion Technology, with four core functions: FFR, IMR, QCA, and surgical evaluation, enabling one-stop acquisition of morphological and functional results as well as the assessment of epicardial and microvascular coronary blood supply function. It provides precise FFR calculations while ensuring efficiency. Additionally, the product is equipped with a dedicated pressure sensor for blood pressure measurement.Not only does it significantly improve calculation accuracy, but it also covers a richer variety of lesion types compared to similar products., providing intelligent, precise, and reliable decision support for surgeons.
At the 2025 China Medical Equipment Conference and Medical Equipment Exhibition, RaysightMed not only showcased its latest achievements and innovative capabilities in the field of cardiovascular equipment technology but also engaged in in-depth exchanges and collaborations with numerous industry peers. Together, they explored the future development trends and cooperation opportunities in interventional cardiovascular diagnosis and treatment technologies. Looking ahead, RaysightMed will continue...Strengthening the AI large model + surgical robot technology barriers, perfecting the ecosystem of the cardiovascular precision diagnosis and treatment platform, "Precisely safeguarding every cardiovascular."。
